Advertisement
Advertisement
AQST
Aquestive Therapeutics, Inc. Common Stock
3.94
USDSponsored
+0.02
+0.51%
Aug 07, 15:58 UTC -4
Closed
After-Market
3.95
+0.01
+0.25%
AQST Earnings Reports
Positive Surprise Ratio
AQST beat 16 of 32 last estimates.
50%
Next Report
In 2 Days
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$11.65M
/-$0.10
Implied change from Q1 26 (Revenue/ EPS)
-19.38%
/+42.86%
Implied change from Q2 25 (Revenue/ EPS)
+16.42%
/-28.57%
Aquestive Therapeutics, Inc. Common Stock earnings per share and revenue
On May 13, 2026, AQST reported earnings of -0.07 USD per share (EPS) for Q1 26, beating the estimate of -0.13 USD, resulting in a 49.96% surprise. Revenue reached 14.45 million, compared to an expected 11.11 million, with a 29.98% difference. The market reacted with a +1.20% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 11.65 million USD, implying an increase of 42.86% EPS, and decrease of -19.38% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Aquestive Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Aquestive Therapeutics, Inc. Common Stock reported EPS of -$0.07, beating estimates by 49.96%, and revenue of $14.45M, 29.98% above expectations.
How did the market react to Aquestive Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 1.2%, changed from $4.18 before the earnings release to $4.23 the day after.
When is Aquestive Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 11, 2026.
What are the forecasts for Aquestive Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, Aquestive Therapeutics, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of $11.65M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement